H.-J. Senn

5.8k total citations · 1 hit paper
41 papers, 1.9k citations indexed

About

H.-J. Senn is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, H.-J. Senn has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in H.-J. Senn's work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (5 papers). H.-J. Senn is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (5 papers). H.-J. Senn collaborates with scholars based in Switzerland, Germany and Italy. H.-J. Senn's co-authors include Beat Thürlimann, Kurt Wüthrich, Giuseppe Curigliano, Marco Colleoni, Michael Gnant, Carsten Denkert, Harold J. Burstein, Richard D. Gelber, Sibylle Loibl and Martine Piccart and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer.

In The Last Decade

H.-J. Senn

39 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

2019 438 citations Harold J. Burstein, Giuseppe Curigliano et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H.-J. Senn Switzerland	20	856	672	569	264	240	41	1.9k
Jürgen Mattern Germany	26	1.1k 1.2×	643 1.0×	1.1k 2.0×	380 1.4×	148 0.6×	52	2.1k
Carsten Rose Sweden	28	1.2k 1.3×	998 1.5×	602 1.1×	514 1.9×	275 1.1×	69	2.4k
Dona Alberti United States	30	1.0k 1.2×	387 0.6×	1.4k 2.4×	419 1.6×	273 1.1×	90	2.8k
Joseph C. Allegra United States	27	1.0k 1.2×	685 1.0×	470 0.8×	300 1.1×	180 0.8×	67	2.3k
Barry R. Goldspiel United States	31	1.4k 1.7×	272 0.4×	1.2k 2.2×	335 1.3×	209 0.9×	66	3.1k
Moïse Namer France	25	1.8k 2.1×	1.1k 1.6×	437 0.8×	419 1.6×	326 1.4×	62	2.8k
Khalil Zaman Switzerland	28	991 1.2×	476 0.7×	483 0.8×	379 1.4×	160 0.7×	100	2.0k
Gregory D. Ayers United States	28	792 0.9×	401 0.6×	961 1.7×	317 1.2×	291 1.2×	55	2.7k
David J. Kerr United Kingdom	21	790 0.9×	207 0.3×	748 1.3×	318 1.2×	189 0.8×	38	2.4k
Jonghan Yu South Korea	23	560 0.7×	579 0.9×	352 0.6×	159 0.6×	192 0.8×	109	1.5k

Countries citing papers authored by H.-J. Senn

Since Specialization

Citations

This map shows the geographic impact of H.-J. Senn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.-J. Senn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.-J. Senn more than expected).

Fields of papers citing papers by H.-J. Senn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.-J. Senn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.-J. Senn. The network helps show where H.-J. Senn may publish in the future.

Co-authorship network of co-authors of H.-J. Senn

This figure shows the co-authorship network connecting the top 25 collaborators of H.-J. Senn. A scholar is included among the top collaborators of H.-J. Senn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.-J. Senn. H.-J. Senn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burstein, Harold J., Giuseppe Curigliano, Sibylle Loibl, et al.. (2019). Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology. 30(10). 1541–1557. 438 indexed citations breakdown →

Cuzick, Jack, Mangesh A. Thorat, Cristina Bosetti, et al.. (2014). Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology. 26(1). 47–57. 264 indexed citations

Senn, H.-J. & R. Morant. (2008). Chemoprevention of breast and prostate cancers: where do we stand?. Annals of Oncology. 19. vii234–vii237. 5 indexed citations

Goldhirsch, A., Alan S. Coates, Richard D. Gelber, et al.. (2006). First—select the target: better choice of adjuvant treatments for breast cancer patients. Annals of Oncology. 17(12). 1772–1776. 82 indexed citations

Glaus, A, Beat Thürlimann, Thomas Ruhstaller, et al.. (2006). Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Annals of Oncology. 17(5). 801–806. 70 indexed citations

Senn, H.-J., Beat Thürlimann, Aron Goldhirsch, et al.. (2003). Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. The Breast. 12(6). 569–582. 30 indexed citations

Engel, Jutta, Renate Eckel, Jacqueline Kerr, et al.. (2003). The process of metastasisation for breast cancer. European Journal of Cancer. 39(12). 1794–1806. 124 indexed citations

Schoumacher, Fabrice, et al.. (2001). BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer. Swiss Medical Weekly. 131(1516). 223–226. 12 indexed citations

Koeberle, Dieter, et al.. (1999). Pamidronate treatment in patients with malignant osteolytic bone disease and pain. Supportive Care in Cancer. 7(1). 21–27. 35 indexed citations

10.

Castiglione, Monica, et al.. (1999). Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive Care in Cancer. 7(3). 149–153. 13 indexed citations

11.

Senn, H.-J., Rudolf Maibach, M. Castiglione, et al.. (1997). Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.. Journal of Clinical Oncology. 15(7). 2502–2509. 9 indexed citations

12.

Castiglione‐Gertsch, Monica, Martin Tattersall, A Hacking, et al.. (1997). Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. European Journal of Cancer. 33(14). 2321–2325. 15 indexed citations

13.

Ludwig, Heinz, Asaf Cohen, Aaron Polliack, et al.. (1995). Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Annals of Oncology. 6(5). 467–476. 69 indexed citations

14.

Bernhard, Jürg, Alan S. Coates, M. Castiglione, et al.. (1994). Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation. Annals of Oncology. 5(1). 65–74. 22 indexed citations

15.

Morant, R., et al.. (1994). Treatment of Patients with Metastatic Renal Cell Carcinoma with Subcutaneous Recombinant Interferon-Alpha 2b and Continuous Infusion of Recombinant lnterleukin-2: A Phase II Study. Oncology Research and Treatment. 17(3). 254–260. 3 indexed citations

16.

Müller, Sabine, H.-J. Senn, Bernard Gsell, et al.. (1994). The Formation of Diselenide Bridges in Proteins by Incorporation of Selenocysteine Residues: Biosynthesis and Characterization of (Se)2-Thioredoxin. Biochemistry. 33(11). 3404–3412. 140 indexed citations

17.

Gusterson, B.A., D Jadayel, M.J. O’Hare, et al.. (1994). Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. Annals of Oncology. 5(5). 409–414. 46 indexed citations

18.

Erlichman, Charles, Shai Fine, Ian G. Kerr, et al.. (1993). Experience with 5FU + L-Leucovorin. Advances in experimental medicine and biology. 339. 77–79.

19.

Thürlimann, B., et al.. (1991). Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Intensification of Cytostatic Treatment in Advanced Cancer. Recent results in cancer research. 121. 173–181. 2 indexed citations

20.

Mayr, Agnes, W. F. Jungi, & H.-J. Senn. (1979). A well tolerated oral combination of chlorambucil (LeukeranR), methotrexate, fluorouracil, prednisone (LMFP) in disseminated breast cancer. Cancer Treatment Reviews. 6. 115–120. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact